Liver disease is one of the most pressing, yet under-recognised, health challenges of our time. In the UK alone, liver disease is now the third most common cause of premature death and it’s rising faster than any other major disease (1). One of the most common misconceptions is that it only affects people with alcohol dependency. In fact, chronic liver disease includes a spectrum of conditions, including metabolic dysfunction-associated steatotic liver disease (a.k.a. fatty liver disease), autoimmune conditions, viral hepatitis, and more, which together impact millions.
While the emergence of promising new pharmacological treatments is a welcome development, these therapies are not without financial costs or side effects, and they are also not appropriate for all patient groups. Thankfully, there’s growing evidence of the benefit of non-pharmacological interventions, especially those that target lifestyle, behaviour, and the social determinants of health.
The case for social prescriptions in liver disease
Social prescribing, where clinicians refer patients to non-medical services such as exercise programs, peer support, nutritionists, or housing support, is gaining traction across the NHS and internationally. In the context of liver disease, the evidence, though still emerging, is compelling:
- Exercise interventions have been shown to improve liver function, increase muscle mass, and reduce hospitalisation in people with cirrhosis (2).
- Integrated addiction support and social care reduce alcohol intake and improve survival among people with alcohol-related liver disease (3).
- People with stronger social support networks live longer and report better mental health than those who are isolated (4).
- Mental health interventions, such as group therapy, can significantly improve quality of life (5).
Though these approaches don’t replace medication or clinical oversight, they add a layer of meaningful, personalised care, which is particularly valuable in a disease area where health inequalities and psychosocial factors play a significant role.
Cost, community, and early action
Social prescriptions also have broader societal benefits. They can reduce strain on GP appointments, cut unplanned hospital admissions, and offer cost savings when targeted effectively (6). These interventions help address the non-clinical drivers of disease progression, including isolation, financial insecurity, and mental ill-health, which traditional medical pathways are unequipped to deal with.
We shouldn’t overlook the importance of early identification. Since 1970, liver disease mortality in the UK has increased by over 400% (7). Too often, diagnoses come late, when disease is advanced, and treatment options are limited. That’s why our response must be twofold:
1) Proactively identify at-risk individuals earlier and offer evidence-based, conservative treatments, including social and behavioural support, before irreversible damage occurs.
b) Ensure those with advanced disease receive appropriate care, including anti-fibrotics, and are enrolled in early surveillance for liver cancer.
More complete liver care
We believe in data-driven, human-centred approaches to managing chronic liver disease. That means using all the tools available, including clinical, social, behavioural, political, and economic, to turn the tide on one of the most pressing public health issues today.
Sources:
(1) British Liver Trust. Liver disease in numbers – key facts and statistics. 2023. https://britishlivertrust.org.uk/information-and-support/statistics/
(2) Aamann L, et al. Resistance training increases muscle strength and muscle size in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology. 2020;18(5):1179–1187.e6. https://pubmed.ncbi.nlm.nih.gov/31394282/
(3) Aamann L, et al. Reduced 3-year risk of hospital admission and mortality after 12 weeks of resistance training in cirrhosis. Journal of Gastroenterology & Hepatology. 2023. https://pubmed.ncbi.nlm.nih.gov/36740964/#:~:text=Conclusion%3A%20Twelve%20weeks%20of%20resistance,and%20larger%20studies%20are%20warranted.
(4) Sengupta S, et al. The impact of integrated care on clinical outcomes in patients with alcohol-associated liver disease: Early outcomes from a multidisciplinary clinic. Hepatology Communications. 2025. https://pubmed.ncbi.nlm.nih.gov/39927894/
(5) Askgaard G, et al. Social support and risk of mortality in cirrhosis: A cohort study. JHEP Reports. 2023 https://pubmed.ncbi.nlm.nih.gov/36644236/
(6) Verma M, et al. A Behavioral Health Program for Alcohol Use Disorder, Substance Abuse, and Depression in Chronic Liver Disease. Hepatology Communications. 2019 https://pubmed.ncbi.nlm.nih.gov/31061953/
7) Polley MJ, et al. A review of the evidence assessing impact of social prescribing on healthcare demand and cost implications. University of Westminster, 2017. https://westminsterresearch.westminster.ac.uk/item/q1455
